Aktis Oncology is developing novel alpha radiotherapies to improve upon the efficacy of conventional solid tumor therapies, while limiting toxicity. The company has developed proprietary platforms to discover best-in-class tumor targeting agents designed with optimal pharmacology for delivering alpha radiotherapy. Aktis Oncology targeting agents are highly tumor penetrant but clear from other areas of the body quickly, to maximize tumor elimination while minimizing potential side effects of treatment.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/19/21 | $72,000,000 | Series A |
Bristol-Myers Squibb EcoR1 Capital  MPM Capital Novartis Venture Funds Octagon Capital The Column Group Vida Ventures | undisclosed |
| 08/25/22 | $84,000,000 | Series A Extension |
ArrowMark Partners Bristol Myers Squibb Cowen Healthcare Investments EcoR1 Capital Merck Global Health Innovation Fund Mirae Asset Venture Investment MPM Capital MRL Ventures Fund Novartis Octagon Capital Pappas Capital TCG Crossover Timefolio Investment Vida Ventures | undisclosed |
| 10/17/24 | $175,000,000 | Series B |
Avidity Partners Bristol Myers Squibb Eli Lilly and Company Janus Henderson Investors MRL Ventures Fund RA Capital Management RTW Investments T. Rowe Price Associates | undisclosed |
